Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug (NCT06641076)
A Phase 3, Parallel-group, Randomized, Double-blind, 3-arm, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Subcutaneous Sonelokimab in Male and Female Participants Aged 18 Years and Over With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs
🩺 Plain-English Summary (8th-Grade Level)
This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.
Who can join: Review the eligibility criteria below.
Location: Clinical Site — Avondale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (182 Sites)
Showing the first 25 of 182 sites.
- Clinical Site — Avondale, Arizona
- Clinical Site — Chandler, Arizona
- Clinical Site — Flagstaff, Arizona
- Clinical Site — Mesa, Arizona
- Clinical Site — Phoenix, Arizona
- Clinical Site — Scottsdale, Arizona
- Clinical Site — Tucson, Arizona
- Clinical Site — San Diego, California
- Clinical Site — Upland, California
- Clinical Site — Avon Park, Florida
- Clinical Site — Clearwater, Florida
- Clinical Site — Hialeah, Florida
- Clinical Site — Tampa, Florida
- Clinical Site — Springfield, Illinois
- Clinical Site — Lake Charles, Louisiana
- Clinical Site — Baltimore, Maryland
- Clinical Site — Grand Blanc, Michigan
- Clinical Site — Leland, North Carolina
- Clinical Site — Salisbury, North Carolina
- Clinical Site — Statesville, North Carolina
- Clinical Site — Middleburg Heights, Ohio
- Clinical Site — Portland, Oregon
- Clinical Site — Memphis, Tennessee
- Clinical Site — Allen, Texas
- Clinical Site — Colleyville, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Arthritis, Psoriatic
- A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice — Buenos Aires,
- A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis — Jonesboro, Arkansas
- A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease — Avondale, Arizona
- A Study of Guselkumab in Participants With Active Psoriatic Arthritis — Birmingham, Alabama
- A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis — Glendale, Arizona
Explore by condition: All Arthritis, Psoriatic clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.